title: [Evolution of Sjögren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin].
abstract: Hepatitis C virus is one of the most likely candidates as a potential pathogenic agent causing Sjogren's syndrome (SS) in a subset of patients. Nobody has until now described the evolution of SS associated with HCV when chronic hepatitis C is treated with antiviral therapy, interferon being an auto-immunity inductor. This is the purpose of our study.
  
  
  METHODS
  Prospective study of 12 patients with a HCV-associated SS defined as certain according to the first european criteria and treated with interferon or interferon/ribavirin for their chronic hepatitis C.
  
  
  RESULTS
  More than fifty percent of these patients developed a severe immunological complication especially when they were treated with interferon alone. Ribavirin may have had a protective role on interferon-mediated immunological complications. These complications went on after cessation of therapy. Sicca syndrome was improved only in the patients treated with the association (in 50% of the cases), but these patients also had a sustained virological response. It is difficult to tell if this improvement was due to the hepatitis C virus eradication or ribavirin treatment.
  
  
  CONCLUSIONS
  Hepatitis C virus is implicated in the development of SS in a specific subset of patients for which we can propose the term SS "secondary to HCV" and this disease is not utterly benign especially after the introduction of interferon therapy. Ribavirin when associated with interferon gives a significative sustained virological response and could lower the incidence of immunological interferon-mediated complications with a favorable outcome of sicca syndrome.
authors.affiliation: Service de médecine interne A, CHU de Limoges, 87000 Limoges, France.
authors.forename: V
authors.initials: V
authors.lastname: Doffoël-Hantz
authors.forename: V
authors.initials: V
authors.lastname: Loustaud-Ratti
authors.forename: M
authors.initials: M
authors.lastname: Ramos-Casals
authors.forename: S
authors.initials: S
authors.lastname: Alain
authors.forename: H
authors.initials: H
authors.lastname: Bezanahary
authors.forename: E
authors.initials: E
authors.lastname: Liozon
authors.forename: A L
authors.initials: AL
authors.lastname: Fauchais
authors.forename: E
authors.initials: E
authors.lastname: Vidal
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use*; D012859:Sjogren's Syndrome / Q000175:diagnosis / Q000209:etiology* / Q000276:immunology / Q000821:virology; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons